CytomX Therapeutics
CTMX
110 hedge funds and large institutions have $236M invested in CytomX Therapeutics in 2021 Q4 according to their latest regulatory filings, with 21 funds opening new positions, 27 increasing their positions, 44 reducing their positions, and 25 closing their positions.
0.75% more ownership
Funds ownership: 82.85% → 83.6% (+0.75%)
4% less funds holding
Funds holding: 114 → 110 (-4)
14% less capital invested
Capital invested by funds: $275M → $236M (-$38.4M)
16% less first-time investments, than exits
New positions opened: 21 | Existing positions closed: 25
17% less call options, than puts
Call options by funds: $238K | Put options by funds: $287K
39% less repeat investments, than reductions
Existing positions increased: 27 | Existing positions reduced: 44
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BI
BVF Inc
San Francisco,
California
|
+$34M |
| 2 |
RI
RTW Investments
New York
|
+$27.1M |
| 3 |
RCMNY
Rubric Capital Management (New York)
New York
|
+$14.1M |
| 4 |
O
OrbiMed
New York
|
+$8.16M |
| 5 |
Millennium Management
New York
|
+$1.93M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
RCM
RA Capital Management
Boston,
Massachusetts
|
-$17.8M |
| 2 |
Victory Capital Management
San Antonio,
Texas
|
-$16.6M |
| 3 |
CS
Candriam SCA
Strassen, Luxembourg,
Luxembourg
|
-$9.05M |
| 4 |
GPP
Great Point Partners
Greenwich,
Connecticut
|
-$7.63M |
| 5 |
State Street
Boston,
Massachusetts
|
-$7.6M |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
126
Zurich Cantonal Bank
Zurich,
Switzerland
| – | -$30K | -5,922 | Closed |
|
127
Macquarie Group
Sydney, NSW 2000,
Australia
| – | -$25K | -4,853 | Closed |
|
|
MCM
128
Manchester Capital Management
Manchester,
Vermont
| – | -$16K | -3,239 | Closed |
|
|
FQ
129
First Quadrant
Glendale,
California
| – | -$16K | -3,100 | Closed |
|
130
Canada Life
Winnipeg,
Manitoba, Canada
| – | -$13K | -2,623 | Closed |
|
|
PCM
131
Penserra Capital Management
Orinda,
California
| – | -$7K | -1,490 | Closed |
|
|
LWM
132
Liberty Wealth Management
Oakland,
California
| – | -$3K | -500 | Closed |
|
133
Osaic Holdings
Scottsdale,
Arizona
| – | -$6 | -1 | -7% |
|
134
US Bancorp
Minneapolis,
Minnesota
| – | +$293 | +50 | New |
|
CTMX Hedge Fund Activity: Q4 2021 in Review
110 of the 6,498 institutional investors tracked by Wall St. Rank reported a position in CytomX Therapeutics (CTMX) for Q4 2021, worth a combined $236M — down 14% from $275M a quarter earlier.
Sellers outnumbered buyers: 25 funds closed out of CTMX and 21 opened new positions — a net loss of 4 holders — while 44 trimmed existing stakes and 27 added.
The largest buyer was BVF Inc, opening a new position worth an estimated $34M. The largest seller was RA Capital Management, exiting entirely with an estimated $17.8M sold.
- 110 institutional investors held CytomX Therapeutics (CTMX) as of Q4 2021, down from 114 in Q3 2021.
- Funds reported $236M of CytomX Therapeutics stock for Q4 2021, down 14% quarter-over-quarter.
- 21 funds opened new CytomX Therapeutics positions in Q4 2021 and 25 closed out, a net change of -4 holders.
- The largest CytomX Therapeutics buyer in Q4 2021 was BVF Inc, an estimated $34M added.
- The largest CytomX Therapeutics seller in Q4 2021 was RA Capital Management, an estimated $17.8M sold.
Based on aggregated 13F filings for Q4 2021.